RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $20
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Ben Hendrix maintains Surgery Partners (NASDAQ:SGRY) with a Outperform and lowers the price target from $31 to $20.
RBC Capital analyst Ben Hendrix maintains Surgery Partners (NASDAQ:SGRY) with a Outperform and lowers the price target from $31 to $20.